Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.42 |
| ▸ | ITGAV | P06756 | 15/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7401324 | 1.00 | ITGB3 (0.42) | ITGB3ITGA2BITGAVSMPD1EGLN2 | |
| SCHEMBL7396575 | 0.98 | ITGB3 (0.43) | ITGB3ITGA2BITGAVSMPD1EGLN2 | |
| SCHEMBL7982190 | 0.90 | ITGB3 (0.43) | ITGB3ITGA2BITGAV | |
| SCHEMBL7969118 | 0.88 | ITGB3 (0.44) | ITGB3ITGA2BITGAVEGLN2EGLN1 | |
| SCHEMBL6111432 | 0.85 | ITGB3 (0.46) | ITGB3ITGA2BITGAV | |
| SCHEMBL7982195 | 0.83 | ITGB3 (0.43) | ITGB3ITGA2BITGAVEGLN2EGLN1 | |
| Hydrochloric Acid SCHEMBL7450972 | 0.80 | ITGB3 (0.47) | ITGB3ITGA2BITGAVSMPD1EGLN2 | |
| Hydrochloric Acid SCHEMBL8643329 | 0.80 | ITGB3 (0.51) | ITGB3ITGA2BITGAVSMPD1 | |
| Hydrochloric Acid SCHEMBL8643309 | 0.80 | ITGB3 (0.51) | ITGB3ITGA2BITGAVSMPD1 | |
| SCHEMBL7401332 | 0.79 | ITGB3 (0.59) | ITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |